Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GLYCOMED/SANKYO $10.5 MIL. AGREEMENT FOR CELL ADHESION INHIBITOR

Executive Summary

GLYCOMED/SANKYO $10.5 MIL. AGREEMENT FOR CELL ADHESION INHIBITOR research was announced by Glycomed July 19. The three- year agreement calls for Sankyo to take an equity stake in Alameda, Calif.-based Glycomed, make an upfront payment and provide research support. Glycomed will receive an additional $5 mil. for each compound developed under the agreement. In exchange, Sankyo will have exclusive marketing rights to cell adhesion compounds in the Far East.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel